ImaginAb

About:

ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.

Website: http://imaginab.com

Top Investors: Novartis Venture Fund, Mérieux Equity Partners, Parker Institute for Cancer Immunotherapy, Adage Capital Management, Theravance Biopharma

Description:

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.